Drug Topics Newsletter

To view this email as a web page, click here.

PHARMACISTS' REPORT

Mayzent (Siponimod) Granted FDA Approval for SPMS

The next-generation oral drug is the first to be approved specifically for secondary progressive multiple sclerosis in more than 15 years.

Patients with Cognitive Impairment Less Likely to Get OACs

Study finds different anticoagulation treatment levels for patients with cognitive problems.

WHERE SPECIALTY PHARMACY MEETS

Join us for the 2019 Specialty Pharmacy Summit (April 29 – May 2, Wynn/Encore, Las Vegas) for four full days of business workshops, educational seminars, engaging exhibits and CE credits, plus unmatched networking and social events. Learn more at

www.asembiasummit.com

Coping with Patient Death

Grief: An under-recognized reality that deserves serious attention.

Opinion: Upholding Our Oath

Two Arizona pharmacists made headlines when it seems they may have not adhered to the Oath of the Pharmacist.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT